Patents by Inventor Donna A.A. Wilton
Donna A.A. Wilton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11608354Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: GrantFiled: February 22, 2021Date of Patent: March 21, 2023Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
-
Publication number: 20210179655Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: ApplicationFiled: February 22, 2021Publication date: June 17, 2021Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A.A. Wilton, Mandy Loo, Patrick J. Brassil
-
Patent number: 10961267Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: GrantFiled: August 29, 2019Date of Patent: March 30, 2021Assignee: Theravance Biopharma R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
-
Publication number: 20210032250Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: July 13, 2020Publication date: February 4, 2021Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: DANIEL D. LONG, DONNA A.A. WILTON, MANDY M. LOO
-
Patent number: 10745405Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.Type: GrantFiled: May 22, 2018Date of Patent: August 18, 2020Assignee: Theravance Biopharma R&D IP, LLCInventors: Daniel D. Long, Donna A. A. Wilton, Mandy M. Loo, Ryan Hudson, Patrick J. Brassil
-
Publication number: 20190389895Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: ApplicationFiled: August 29, 2019Publication date: December 26, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A.A. Wilton, Mandy Loo, Patrick J. Brassil
-
Patent number: 10472366Abstract: The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.Type: GrantFiled: March 7, 2018Date of Patent: November 12, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Daniel D. Long, Donna A.A. Wilton, Mandy M. Loo
-
Patent number: 10435428Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: GrantFiled: November 22, 2016Date of Patent: October 8, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
-
Publication number: 20180339990Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: May 22, 2018Publication date: November 29, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: DANIEL D. LONG, DONNA A.A. WILTON, MANDY M. LOO, RYAN HUDSON, PATRICK J. BRASSIL
-
Publication number: 20180258094Abstract: The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: March 7, 2018Publication date: September 13, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: DANIEL D. LONG, DONNA A.A. WILTON, MANDY M. LOO
-
Publication number: 20180193338Abstract: In one aspect, the invention relates to compounds having the formula I: where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: November 8, 2017Publication date: July 12, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melissa Fleury, Anne-Marie Beausoleil, Adam D. Hughes, Daniel D. Long, Donna A.A. Wilton
-
Patent number: 10005740Abstract: In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: GrantFiled: September 6, 2017Date of Patent: June 26, 2018Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melissa Fleury, Anne-Marie Beausoleil, Adam D. Hughes, Daniel D. Long, Donna A. A. Wilton
-
Publication number: 20180118696Abstract: In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: September 6, 2017Publication date: May 3, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melissa Fleury, Anne-Marie Beausoleil, Adam D. Hughes, Daniel D. Long, Donna A.A. Wilton
-
Patent number: 9839639Abstract: In one aspect, the invention relates to compounds having the formula I: where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: GrantFiled: January 19, 2017Date of Patent: December 12, 2017Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melissa Fleury, Anne-Marie Beausoliel, Adam D. Hughes, Daniel D. Long, Donna A. A. Wilton
-
Patent number: 9783507Abstract: In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: GrantFiled: January 30, 2017Date of Patent: October 10, 2017Assignee: Theravance Biopharma R&D IP, LLCInventors: Melissa Fleury, Anne-Marie Beausoliel, Adam D. Hughes, Daniel D. Long, Donna A. A. Wilton
-
Publication number: 20170189399Abstract: In one aspect, the invention relates to compounds having the formula I: where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: January 19, 2017Publication date: July 6, 2017Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melissa Fleury, Anne-Marie Beausoliel, Adam D. Hughes, Daniel D. Long, Donna A.A. Wilton
-
Publication number: 20170145044Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.Type: ApplicationFiled: November 22, 2016Publication date: May 25, 2017Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Ryan Hudson, Daniel D. Long, Donna A.A. Wilton, Mandy Loo
-
Publication number: 20170137388Abstract: In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: January 30, 2017Publication date: May 18, 2017Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melissa Fleury, Anne-Marie Beausoliel, Adam D. Hughes, Daniel D. Long, Donna A.A. Wilton
-
Patent number: 9593110Abstract: In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: GrantFiled: January 29, 2015Date of Patent: March 14, 2017Assignee: Theravence Biopharma R&D IP, LLCInventors: Melissa Fleury, Anne-Marie Beausoliel, Adam D. Hughes, Daniel D. Long, Donna A. A. Wilton
-
Patent number: 9585882Abstract: In one aspect, the invention relates to compounds having the formula I: where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: GrantFiled: January 29, 2015Date of Patent: March 7, 2017Assignee: Theravance Biopharma R&D IP, LLCInventors: Melissa Fleury, Anne-Marie Beausoliel, Adam D. Hughes, Daniel D. Long, Donna A. A. Wilton